Patents by Inventor Ryan James Darling

Ryan James Darling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CGRP ANTIBODIES
    Publication number: 20170073403
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 16, 2017
    Applicant: Eli Lilly and Company
    Inventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
  • Method to treat migraines using CGRP antibodies
    Patent number: 9505838
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: November 29, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
  • Fibroblast growth factor 21 variant, composition , and uses thereof
    Patent number: 9422353
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: August 23, 2016
    Assignee: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • CGRP ANTIBODIES
    Publication number: 20150259415
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 17, 2015
    Applicant: ELI LILLY AND COMPANY
    Inventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
  • CGRP antibodies
    Patent number: 9073991
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: July 7, 2015
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
  • FIBROBLAST GROWTH FACTOR 21 VARIANTS
    Publication number: 20150141327
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 21, 2015
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Fibroblast growth factor 21 proteins
    Patent number: 8927492
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: January 6, 2015
    Assignee: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Fibroblast growth factor 21 variants
    Patent number: 8883726
    Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: November 11, 2014
    Assignee: Eli Lilly and Company
    Inventors: Craig Duane Dickinson, David Albert Driver, Ryan James Darling, Malgorzata Donata Gonciarz, Radmila Micanovic
  • FIBROBLAST GROWTH FACTOR 21 PROTEINS
    Publication number: 20140228282
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Application
    Filed: April 23, 2014
    Publication date: August 14, 2014
    Applicant: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Fibroblast growth factor 21 proteins
    Patent number: 8741841
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: June 3, 2014
    Assignee: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Homodimeric Proteins
    Publication number: 20140056893
    Abstract: This present invention relates to a homodimeric protein comprising fibroblast growth factor 21 (FGF21) and glucagon-like peptide (GLP-1), pharmaceutical compositions comprising the homodimeric protein, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such homodimeric protein.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 27, 2014
    Applicant: Eli Lilly and Company
    Inventors: Tamer Coskun, Ryan James Darling, Malgorzata Donata Gonciarz, Jorge Alsina-Fernandez
  • FIBROBLAST GROWTH FACTOR 21 PROTEINS
    Publication number: 20130330336
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Application
    Filed: June 5, 2013
    Publication date: December 12, 2013
    Applicant: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • FIBROBLAST GROWTH FACTOR 21 VARIANTS
    Publication number: 20130324460
    Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
    Type: Application
    Filed: August 13, 2013
    Publication date: December 5, 2013
    Applicant: Eli Lilly and Company
    Inventors: Craig Duane DICKINSON, David Albert DRIVER, Ryan James DARLING, Malgorzata Donata GONCIARZ, Radmila MICANOVIC
  • Fibroblast growth factor 21 variants having improved pharmacological potency and/or improved pharmaceutical stability
    Patent number: 8541369
    Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: September 24, 2013
    Assignee: Eli Lilly and Company
    Inventors: Craig Duane Dickinson, David Albert Driver, Ryan James Darling, Maigorzata Donata Gonciarz, Radmila Micanovic
  • Antibodies to PCSK9 and uses thereof
    Patent number: 8530414
    Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: September 10, 2013
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Ryan James Darling, Barrett Allan
  • ANTIBODIES TO PCSK9 AND USES THEREOF
    Publication number: 20130071405
    Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 21, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Julian Davies, Ryan James Darling, Barrett Allan
  • DKK-1 antibodies
    Patent number: 8148498
    Abstract: The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: April 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Ryan James Darling, Rachelle Jeanette Galvin, Barbara Anne Swanson
  • CGRP ANTIBODIES
    Publication number: 20110305711
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Application
    Filed: June 7, 2011
    Publication date: December 15, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
  • DKK-1 ANTIBODIES
    Publication number: 20100260754
    Abstract: The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1.
    Type: Application
    Filed: April 6, 2010
    Publication date: October 14, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Marcio CHEDID, Ryan James DARLING, Rachelle Jeanette GALVIN, Barbara Anne Swanson